Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies

Pluristyx announced the launch of a project up to $1.4 million, supported and funded by Breakthrough T1D. The project will create and distribute a genetically engineered iPSC line, providing developers with an important new tool that serves as the starting material for manufacturing the next generation of islet replacement therapies.